CARL-WILHELM E. VOGEL
Medical Practice in Honolulu, HI
License number
DC MD18368
Issued Date
Mar 16, 1990
Expiration Date
Dec 31, 2018
Category
MEDICINE
Type
MEDICINE AND SURGERY
Address
Address
University Of Hawaii Cancer Ctr, Honolulu, HI 96813
Professional information
Dr. Carl-Wilhelm E Vogel, Honolulu HI - MD (Doctor of Medicine)
Specialties:
Clinical Pathology
Address:
1236 Lauhala St STE 510, Honolulu 96813
(808) 564-5979 (Phone), (808) 586-3052 (Fax)
CANCER RESEARCH CENTER OF HAWAII
1236 Lauhala St, Honolulu 96813
(808) 586-3015 (Phone), (808) 586-3009 (Fax)
(808) 564-5979 (Phone), (808) 586-3052 (Fax)
CANCER RESEARCH CENTER OF HAWAII
1236 Lauhala St, Honolulu 96813
(808) 586-3015 (Phone), (808) 586-3009 (Fax)
Certifications:
Clinical Pathology, 1997
Awards:
Healthgrades Honor Roll
Languages:
English
Education:
Medical School
University of Hamburg / Medical Faculty
Univ Hosps Kiel/Hamburg
Georgetown University
Iu Health University
Inst For Tropical Dis
Scripps Clin & Res Fdn
University of Hamburg / Medical Faculty
Univ Hosps Kiel/Hamburg
Georgetown University
Iu Health University
Inst For Tropical Dis
Scripps Clin & Res Fdn
Human Complement C3 Derivates With Cobra Venom Factor-Like Function
US Patent:
8632780, Jan 21, 2014
Filed:
Apr 29, 2005
Appl. No.:
11/579235
Inventors:
Carl-Wilhelm Vogel - Honolulu HI, US
David C. Fritzinger - Honolulu HI, US
David C. Fritzinger - Honolulu HI, US
Assignee:
University of Hawaii - Honolulu HI
International Classification:
A01K 39/00, A61K 35/14, A61K 38/16, C07K 1/00, C07K 14/00, C07K 16/00, C07K 17/00
US Classification:
4241851, 530350, 530380
Abstract:
A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein can be manipulated to contain at least one of the following CVF functions: increased stability of the C3 convertase and increased resistance to the actions of factors H and/or I. A large number of hybrid C3 proteins containing substitutions in the C-terminal portion of the alpha chain of C3 are presented and tested for the above functions. Methods of treatment of diseases such as reperfusion injury, autoimmune diseases, and other diseases of increased complement activation are presented as well as methods of increasing the effectiveness of gene therapeutics and other therapeutics.
Human Complement C3 Derivates With Cobra Venom Factor-Like Function
US Patent:
2008023, Sep 25, 2008
Filed:
Aug 7, 2007
Appl. No.:
11/890900
Inventors:
Carl-Wilhelm Vogel - Honolulu HI, US
David C. Fritzinger - Honolulu HI, US
David C. Fritzinger - Honolulu HI, US
International Classification:
A61K 38/00, C07K 16/00, C12Q 1/00, C07H 21/04, C12N 15/00
US Classification:
514 12, 530350, 435 4, 536 235, 4353201
Abstract:
A modified human complement C3 protein (C3) is disclosed comprising a substitution of a portion of a human C3 protein, with a corresponding portion of a Cobra Venom Factor protein (CVF) which results in a human C3 protein with CVF functions, but with substantially reduced immunogenicity. Advantageously, the C3 protein can be manipulated to contain at least one of the following CVF functions: increased stability of the C3 convertase and increased resistance to the actions of factors H and/or I. A large number of hybrid C3 proteins containing substitutions in the C-terminal portion of the alpha chain of C3 are presented and tested for the above functions. Methods of treatment of diseases such as reperfusion injury, autoimmune diseases, and other diseases of increased complement activation are presented as well as methods of increasing the effectiveness of gene therapeutics and other therapeutics.
Human Complement C3 Derivatives With Cobra Venom Factor-Like Function
US Patent:
2010017, Jul 15, 2010
Filed:
Nov 15, 2007
Appl. No.:
12/513665
Inventors:
David C. Fritzinger - Honolulu HI, US
Carl-Wilhelm Vogel - Honolulu HI, US
Carl-Wilhelm Vogel - Honolulu HI, US
International Classification:
A61K 38/16, C07K 14/00, C07H 21/04, A61P 43/00, C12N 15/63, C12P 21/02, C12N 5/10, C12N 1/21, C12N 1/19
US Classification:
514 12, 530350, 536 235, 4353201, 435 691, 435367, 435358, 43525233, 43525231, 4352542, 43525421, 43525423, 435348
Abstract:
The invention provides modified human complement C3 proteins, comprising a human C3 protein, wherein amino acid residues in the human C3 protein are substituted with a corresponding portion of a Cobra Venom Factor (CVF) protein, and wherein one or more amino acid residues in the CVF portion of the modified human complement C3 protein are further modified.